Novartis expands optogenetics portfolio with acquisition of Arctos Medical
The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of optogenetics as the basis of successful therapeutics.
Over the current book year the total revenu from the company based in Basel will be 51.95 billion CHF (consensus estimates). This is slightly more than 2021's revenue of 49.9 billion CHF.
Historical revenues and results Novartis plus estimates 2021
The analysts expect for 2021 a net profit of 14.06 billion CHF. For this year the consensus of the result per share is a profit of 6.33 CHF. The PE-ratio therefore is 12.11.
Huge dividend Novartis
Per share the analysts anticipate on a dividend of 3.29 CHF per share. Thus the dividend yield equals 4.29 percent. The average dividend yield of the pharmaceutical companies is a moderate 1.37 percent.Most recent target prices around 79 CHF
The most recent recommendations for the pharmaceutical company are from Kepler Capital Markets, JP Morgan and Goldman Sachs .Based on the current number of outstanding shares Novartis 's market capitalization is 173.57 billion CHF. -2
At 13.48 the stock trades 0.91 percent higher at 76.63 CHF.Historical stock prices Novartis past 10 years
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
